About Prometheus Biosciences
Prometheus Biosciences is a company based in San Diego (United States) founded in 2016 by Stephan Targan was acquired by Merck in April 2023.. Prometheus Biosciences has raised $130 million across 1 funding round from investors including Merck, Nestlé and Cedars Sinai. Prometheus Biosciences operates in a competitive market with competitors including Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others.
- Headquarter San Diego, United States
- Founders Stephan Targan
- Stage Public
-
Sectors
Healthcare
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Unlock access to complete
Unlock access to complete
Leadership Team
442 people
Software Development Team
251 people
Product Management Team
73 people
Sales and Marketing
73 people
Senior Team
64 people
Data Analysis and Operations Team
63 people
Operations Team
54 people
Finance and Accounting
30 people
Unlock access to complete
Funding Insights of Prometheus Biosciences
Prometheus Biosciences has successfully raised a total of $130M through 1 strategic funding round. The most recent funding activity was a Series D round of $130 million completed in November 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 1
- Last Round Series D — $130.0M
-
First Round
First Round
(09 Nov 2020)
- Investors Count 10
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2020 | Amount | Series D - Prometheus Biosciences | Valuation | Eventide Funds , RTW Investments |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Prometheus Biosciences
Prometheus Biosciences has secured backing from 11 investors, including institutional and venture fund investors. Prominent investors backing the company include Merck, Nestlé and Cedars Sinai. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Life Sciences focused VC firm investing in the US
|
Founded Year | Domain | Location | |
|
Health-tech companies are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Early-stage startups are invested in by sector-agnostic VC fund.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Prometheus Biosciences
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Prometheus Biosciences
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Prometheus Biosciences Comparisons
Competitors of Prometheus Biosciences
Prometheus Biosciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aclaris Therapeutics, Protagonist Therapeutics, OMass Therapeutics, Enterome and CytoKi Pharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Novel dermatologic therapies are developed for skin conditions.
|
|
| domain | founded_year | HQ Location |
Oral peptide therapeutics are developed for gastrointestinal diseases.
|
|
| domain | founded_year | HQ Location |
Proprietary mass spectrometry technologies are developed for protein assembly analysis.
|
|
| domain | founded_year | HQ Location |
Developer of immunomodulators for cancer and auto-immune diseases
|
|
| domain | founded_year | HQ Location |
Therapeutics for epithelial-based diseases are developed and targeted.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Prometheus Biosciences
Frequently Asked Questions about Prometheus Biosciences
When was Prometheus Biosciences founded?
Prometheus Biosciences was founded in 2016 and raised its 1st funding round 4 years after it was founded.
Where is Prometheus Biosciences located?
Prometheus Biosciences is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Is Prometheus Biosciences a funded company?
Prometheus Biosciences is a funded company, having raised a total of $130M across 1 funding round to date. The company's 1st funding round was a Series D of $130M, raised on Nov 09, 2020.
What does Prometheus Biosciences do?
Prometheus Biosciences was founded in 2016 in San Diego, United States, within the biotechnology sector. Treatments for gastrointestinal diseases, especially bowel-related conditions, are developed through a clinical biobank that includes medical records. Targets for biomarker-defined subclinical GI phenotypes are identified using this resource. Pipeline products are advanced through clinical trial phases to address patient needs in this area.
Who are the top competitors of Prometheus Biosciences?
Prometheus Biosciences's top competitors include Aclaris Therapeutics, Protagonist Therapeutics and Samsung Bioepis.
Who are Prometheus Biosciences's investors?
Prometheus Biosciences has 11 investors. Key investors include Merck, Nestlé, Cedars Sinai, TD Securities, and RTW Investments.